Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.

Abstract: The invention relates to a stable supersaturated aqueous solution comprising bilastine and an selected from glutaric acid, citric acid, ?-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof and to its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to the use of the above organic carboxylic acids to increase the aqueous solubility of bilastine.

Abstract: The invention relates to a cocrystal comprising a) at least bilastine and, b) at least a cocrystal forming compound selected from the group consisting of glutaric acid, adipic acid, sorbic acid, succinic acid, benzoic acid, 4-aminobenzoic acid, L-malic acid, resorcinol, methyl 4-hydroxy benzoate and N-(4-hydroxyphenyl)acetamide and mixtures thereof, or a solvate thereof. The invention further relates to methods for obtaining said cocrystals and to their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to a method for increase the aqueous solubility of the above compounds of formula (I).

Abstract: The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.

Abstract: The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Abstract: The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Abstract: The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: A cocrystal of (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and an amino acid, in particular L-valine or L-2-aminobutyric acid, their preparation processes, as well as the preparation process of Ambrisentan or Darusentan using any of the cocrystals of the invention.

Abstract: The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.

Abstract: The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: The present invention refers to co-crystals of monoacid salts of the pharmaceutical active ingredient named Lapatinib and to processes for the preparation thereof and medical uses.

Abstract: A cocrystal of (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and an amino acid, in particular L-valine or L-2-aminobutyric acid, their preparation processes, as well as the preparation process of Ambrisentan or Darusentan using any of the cocrystals of the invention.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Abstract: Co-crystal of a serotonin reuptake inhibitor, in stable form.

Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.